View Financial HealthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsArix Bioscience 배당 및 자사주 매입배당 기준 점검 0/6Arix Bioscience 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률1.0%자사주 매입 수익률총 주주 수익률1.0%미래 배당 수익률0%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jan 22Arix Bioscience plc Announces Resignation of DirectorsArix Bioscience plc announced that Maureen O'Connell and Isaac Kohlberg have resigned from the Arix Board with effect upon the completion of the Share Purchase.Recent Insider Transactions • Nov 06Independent Non-Executive Chairman recently bought UK£69k worth of stockOn the 2nd of November, Peregrine David Euan Moncreiffe bought around 60k shares on-market at roughly UK£1.15 per share. This transaction amounted to 9.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£409k worth in shares.Reported Earnings • Sep 28First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)First half 2023 results: EPS: UK£0.10 (up from UK£0.24 loss in 1H 2022). Net income: UK£12.5m (up UK£42.5m from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.공고 • Sep 28Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023Arix Bioscience plc announced resignation of Robert Lyne as Chief Executive Officer. He has decided to step down from his position to pursue a new opportunity and will leave the company by the end of 2023.공고 • Sep 15Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023Arix Bioscience plc announced that they will report first half, 2023 results on Sep 27, 2023New Risk • Jul 28New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: UK£89k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Significant insider selling over the past 3 months (UK£89k sold).Recent Insider Transactions • May 04Independent Non-Executive Chairman recently bought UK£77k worth of stockOn the 27th of April, Peregrine David Euan Moncreiffe bought around 75k shares on-market at roughly UK£1.03 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£217k. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£475k worth in shares.Reported Earnings • Apr 26Full year 2022 earnings releasedFull year 2022 results: Net loss: UK£27.6m (loss narrowed 55% from FY 2021).Recent Insider Transactions • Feb 08Independent Non-Executive Chairman recently bought UK£217k worth of stockOn the 6th of February, Peregrine David Euan Moncreiffe bought around 200k shares on-market at roughly UK£1.09 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£398k worth in shares.공고 • Jan 27Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive DirectorArix Bioscience plc announced Dr. Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.Price Target Changed • Nov 16Price target increased to UK£2.56Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 131% above last closing price of UK£1.11. Stock is down 20% over the past year. The company posted a net loss per share of UK£0.48 last year.Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). CEO, General Counsel & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Recent Insider Transactions • Nov 04Independent Non-Executive Chairman recently bought UK£78k worth of stockOn the 27th of October, Peregrine David Euan Moncreiffe bought around 75k shares on-market at roughly UK£1.04 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£103k. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£181k worth in shares.Reported Earnings • Aug 11First half 2022 earnings releasedFirst half 2022 results: Net income: (up UK£38.5m from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year.Reported Earnings • May 06Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: UK£0.48 loss per share (down from UK£0.97 profit in FY 2020). Net loss: UK£61.1m (down 148% from profit in FY 2020). Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 995%. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 27Price target increased to UK£2.56Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 131% above last closing price of UK£1.11. Stock is down 42% over the past year. The company posted earnings per share of UK£0.97 last year.Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Board K. Patel is the most experienced director on the board, commencing their role in 2020. Senior Independent Director Michael Bunbury was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.분석 기사 • Jan 13Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The MarketArix Bioscience plc's ( LON:ARIX ) price-to-earnings (or "P/E") ratio of 4.3x might make it look like a strong buy...Price Target Changed • Oct 07Price target increased to UK£2.56Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 82% above last closing price of UK£1.41. Stock is up 31% over the past year.Executive Departure • Sep 01Managing Director Christian Schetter has left the companyOn the 31st of August, Christian Schetter's tenure as Managing Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Christian's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.Reported Earnings • Aug 13First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)First half 2021 results: Revenue: -UK£32.3m (down 175% from 1H 2020). Net loss: UK£38.5m (down 179% from profit in 1H 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.Executive Departure • May 04Executive Chairman Naseem Amin has left the companyOn the 30th of April, Naseem Amin's tenure as Executive Chairman ended after 1.4 years in the role. As of December 2020, Naseem personally held 240.80k shares (UK£527k worth at the time). A total of 3 executives have left over the last 12 months.공고 • Apr 29Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc. on April 28, 2021. DLA Piper LLP (US) served as Pfizer Inc.’s legal advisor for the transaction, while Cooley LLP served as Amplyx’s legal advisor and Evercore as its financial advisor. Pfizer Inc. (NYSE:PFE) completed the acquisition of an remaining unknown minority stake in Amplyx Pharmaceuticals, Inc. on April 28, 2021.Analyst Estimate Surprise Post Earnings • Mar 10Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 88% growth forecast for the Capital Markets industry in the United Kingdom.Reported Earnings • Mar 10Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)The company reported a soft full year result with weaker revenues and profit margins, although earnings were improved. Full year 2020 results: Revenue: UK£135.8m (down 334% from FY 2019). Net income: UK£126.3m (up UK£196.0m from FY 2019). Profit margin: 93% (down from 120% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.공고 • Mar 04Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021Arix Bioscience plc announced that they will report fiscal year 2020 results on Mar 09, 2021Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to UK£1.93, the stock is trading at a trailing P/E ratio of 13.8x, up from the previous P/E ratio of 11.9x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total returns to shareholders over the past three years were flat.Is New 90 Day High Low • Dec 29New 90-day high: UK£2.22The company is up 99% from its price of UK£1.12 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.30 per share.Recent Insider Transactions • Dec 22Executive Chairman recently bought UK£377k worth of stockOn the 18th of December, Naseem Amin bought around 183k shares on-market at roughly UK£2.06 per share. This was the largest purchase by an insider in the last 3 months. This was Naseem's only on-market trade for the last 12 months.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to UK£2.10, the stock is trading at a trailing P/E ratio of 15.1x, up from the previous P/E ratio of 12.9x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total returns to shareholders over the past three years are 11%.Is New 90 Day High Low • Dec 11New 90-day high: UK£1.96The company is up 104% from its price of UK£0.96 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.30 per share.Valuation Update With 7 Day Price Move • Dec 03Market bids up stock over the past weekAfter last week's 18% share price gain to UK£1.76, the stock is trading at a trailing P/E ratio of 12.6x, up from the previous P/E ratio of 10.7x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total return to shareholders over the past three years is a loss of 7.9%.Major Estimate Revision • Nov 08Analysts update estimatesThe company's losses in 2020 are expected to worsen with analysts lowering their consensus EPS forecasts from -UK£0.004 to -UK£0.099. No change was made to the revenue estimate which at the last update was UK£500.0k. The Capital Markets industry in the United Kingdom is expected to see an average net income growth of 2.6% next year. The consensus price target increased from UK£1.38 to UK£2.34. Share price is up 49% to UK£1.58 over the past week.공고 • Nov 06Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion on November 5, 2020. The consideration will be paid in cash and is subject to certain customary adjustments. The sale of VelosBio is expected to deliver net proceeds of approximately $185 million to Arix Bioscience plc representing a 12x return on Arix's invested capital. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020. Gibson Dunn & Crutcher LLP acted as the legal advisor and J.P. Morgan Securities LLC acted as financial advisor to Merck & Co., Inc. Cooley LLP acted as the legal advisor and Centerview Partners LLC acted as the financial advisor to VelosBio Inc.Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 50% share price gain to UK£1.60, the stock is trading at a trailing P/E ratio of 11.5x, up from the previous P/E ratio of 7.6x. This compares to an average P/E of 18x in the Capital Markets industry in the United Kingdom. Total return to shareholders over the past three years is a loss of 12%.Is New 90 Day High Low • Nov 06New 90-day high: UK£1.60The company is up 109% from its price of UK£0.77 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.19 per share.Price Target Changed • Nov 06Price target raised to UK£1.71Up from UK£1.40, the current price target is an average from 3 analysts. The new target price is 6.9% above the current share price of UK£1.60. As of last close, the stock is up 32% over the past year.Is New 90 Day High Low • Oct 01New 90-day high: UK£1.12The company is up 29% from its price of UK£0.86 on 03 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.20 per share.공고 • Aug 10Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020Arix Bioscience plc announced that they will report first half, 2020 results on Sep 08, 2020지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 ARIX 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: ARIX 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Arix Bioscience 배당 수익률 vs 시장ARIX의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (ARIX)n/a시장 하위 25% (GB)2.1%시장 상위 25% (GB)5.4%업계 평균 (Capital Markets)3.2%분석가 예측 (ARIX) (최대 3년)0%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 ARIX 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 ARIX 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 ARIX 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: ARIX 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YGB 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/12 14:57종가2024/02/12 00:00수익2023/06/30연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Arix Bioscience plc는 9명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Maxim JacobsEdison Investment ResearchYingheng ChenHardman & Co.Dorothea HillHardman & Co.6명의 분석가 더 보기
공고 • Jan 22Arix Bioscience plc Announces Resignation of DirectorsArix Bioscience plc announced that Maureen O'Connell and Isaac Kohlberg have resigned from the Arix Board with effect upon the completion of the Share Purchase.
Recent Insider Transactions • Nov 06Independent Non-Executive Chairman recently bought UK£69k worth of stockOn the 2nd of November, Peregrine David Euan Moncreiffe bought around 60k shares on-market at roughly UK£1.15 per share. This transaction amounted to 9.7% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£409k worth in shares.
Reported Earnings • Sep 28First half 2023 earnings released: EPS: UK£0.10 (vs UK£0.24 loss in 1H 2022)First half 2023 results: EPS: UK£0.10 (up from UK£0.24 loss in 1H 2022). Net income: UK£12.5m (up UK£42.5m from 1H 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
공고 • Sep 28Arix Bioscience plc Announces Resignation of Robert Lyne as Chief Executive Officer, by the End of 2023Arix Bioscience plc announced resignation of Robert Lyne as Chief Executive Officer. He has decided to step down from his position to pursue a new opportunity and will leave the company by the end of 2023.
공고 • Sep 15Arix Bioscience plc to Report First Half, 2023 Results on Sep 27, 2023Arix Bioscience plc announced that they will report first half, 2023 results on Sep 27, 2023
New Risk • Jul 28New minor risk - Insider sellingThere has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: UK£89k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Significant insider selling over the past 3 months (UK£89k sold).
Recent Insider Transactions • May 04Independent Non-Executive Chairman recently bought UK£77k worth of stockOn the 27th of April, Peregrine David Euan Moncreiffe bought around 75k shares on-market at roughly UK£1.03 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£217k. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£475k worth in shares.
Reported Earnings • Apr 26Full year 2022 earnings releasedFull year 2022 results: Net loss: UK£27.6m (loss narrowed 55% from FY 2021).
Recent Insider Transactions • Feb 08Independent Non-Executive Chairman recently bought UK£217k worth of stockOn the 6th of February, Peregrine David Euan Moncreiffe bought around 200k shares on-market at roughly UK£1.09 per share. This transaction amounted to 77% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£398k worth in shares.
공고 • Jan 27Arix Bioscience plc Announces Resignation of Benny Soffer as Non-Executive DirectorArix Bioscience plc announced Dr. Benny Soffer, Non-Executive Director, will step down from the Board on 31 January 2023 in order to spend more time on his other business interests.
Price Target Changed • Nov 16Price target increased to UK£2.56Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 131% above last closing price of UK£1.11. Stock is down 20% over the past year. The company posted a net loss per share of UK£0.48 last year.
Board Change • Nov 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 7 new directors. No experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). CEO, General Counsel & Director Rob Lyne is the most experienced director on the board, commencing their role in 2021. Senior Independent Director Debra Barker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Recent Insider Transactions • Nov 04Independent Non-Executive Chairman recently bought UK£78k worth of stockOn the 27th of October, Peregrine David Euan Moncreiffe bought around 75k shares on-market at roughly UK£1.04 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth UK£103k. Peregrine David Euan has been a buyer over the last 12 months, purchasing a net total of UK£181k worth in shares.
Reported Earnings • Aug 11First half 2022 earnings releasedFirst half 2022 results: Net income: (up UK£38.5m from 1H 2021). Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year.
Reported Earnings • May 06Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: UK£0.48 loss per share (down from UK£0.97 profit in FY 2020). Net loss: UK£61.1m (down 148% from profit in FY 2020). Revenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates by 995%. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 27Price target increased to UK£2.56Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 131% above last closing price of UK£1.11. Stock is down 42% over the past year. The company posted earnings per share of UK£0.97 last year.
Board Change • Apr 27Less than half of directors are independentThere are 8 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Member of Scientific Advisory Board K. Patel is the most experienced director on the board, commencing their role in 2020. Senior Independent Director Michael Bunbury was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
분석 기사 • Jan 13Arix Bioscience plc's (LON:ARIX) Business And Shares Still Trailing The MarketArix Bioscience plc's ( LON:ARIX ) price-to-earnings (or "P/E") ratio of 4.3x might make it look like a strong buy...
Price Target Changed • Oct 07Price target increased to UK£2.56Up from UK£2.30, the current price target is provided by 1 analyst. New target price is 82% above last closing price of UK£1.41. Stock is up 31% over the past year.
Executive Departure • Sep 01Managing Director Christian Schetter has left the companyOn the 31st of August, Christian Schetter's tenure as Managing Director ended after 1.2 years in the role. We don't have any record of a personal shareholding under Christian's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is less than a year, which is considered inexperienced in the Simply Wall St Risk Model.
Reported Earnings • Aug 13First half 2021 earnings released: UK£0.30 loss per share (vs UK£0.38 profit in 1H 2020)First half 2021 results: Revenue: -UK£32.3m (down 175% from 1H 2020). Net loss: UK£38.5m (down 179% from profit in 1H 2020). Over the last 3 years on average, earnings per share has increased by 42% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
Executive Departure • May 04Executive Chairman Naseem Amin has left the companyOn the 30th of April, Naseem Amin's tenure as Executive Chairman ended after 1.4 years in the role. As of December 2020, Naseem personally held 240.80k shares (UK£527k worth at the time). A total of 3 executives have left over the last 12 months.
공고 • Apr 29Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc.Pfizer Inc. (NYSE:PFE) acquired remaining unknown minority stake in Amplyx Pharmaceuticals, Inc. on April 28, 2021. DLA Piper LLP (US) served as Pfizer Inc.’s legal advisor for the transaction, while Cooley LLP served as Amplyx’s legal advisor and Evercore as its financial advisor. Pfizer Inc. (NYSE:PFE) completed the acquisition of an remaining unknown minority stake in Amplyx Pharmaceuticals, Inc. on April 28, 2021.
Analyst Estimate Surprise Post Earnings • Mar 10Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 19%. Earnings per share (EPS) also surpassed analyst estimates. Over the next year, revenue is expected to shrink by 100% compared to a 88% growth forecast for the Capital Markets industry in the United Kingdom.
Reported Earnings • Mar 10Full year 2020 earnings released: EPS UK£0.97 (vs UK£0.54 loss in FY 2019)The company reported a soft full year result with weaker revenues and profit margins, although earnings were improved. Full year 2020 results: Revenue: UK£135.8m (down 334% from FY 2019). Net income: UK£126.3m (up UK£196.0m from FY 2019). Profit margin: 93% (down from 120% in FY 2019). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
공고 • Mar 04Arix Bioscience plc to Report Fiscal Year 2020 Results on Mar 09, 2021Arix Bioscience plc announced that they will report fiscal year 2020 results on Mar 09, 2021
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to UK£1.93, the stock is trading at a trailing P/E ratio of 13.8x, up from the previous P/E ratio of 11.9x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total returns to shareholders over the past three years were flat.
Is New 90 Day High Low • Dec 29New 90-day high: UK£2.22The company is up 99% from its price of UK£1.12 on 30 September 2020. The British market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.30 per share.
Recent Insider Transactions • Dec 22Executive Chairman recently bought UK£377k worth of stockOn the 18th of December, Naseem Amin bought around 183k shares on-market at roughly UK£2.06 per share. This was the largest purchase by an insider in the last 3 months. This was Naseem's only on-market trade for the last 12 months.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to UK£2.10, the stock is trading at a trailing P/E ratio of 15.1x, up from the previous P/E ratio of 12.9x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total returns to shareholders over the past three years are 11%.
Is New 90 Day High Low • Dec 11New 90-day high: UK£1.96The company is up 104% from its price of UK£0.96 on 11 September 2020. The British market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.30 per share.
Valuation Update With 7 Day Price Move • Dec 03Market bids up stock over the past weekAfter last week's 18% share price gain to UK£1.76, the stock is trading at a trailing P/E ratio of 12.6x, up from the previous P/E ratio of 10.7x. This compares to an average P/E of 19x in the Capital Markets industry in the United Kingdom. Total return to shareholders over the past three years is a loss of 7.9%.
Major Estimate Revision • Nov 08Analysts update estimatesThe company's losses in 2020 are expected to worsen with analysts lowering their consensus EPS forecasts from -UK£0.004 to -UK£0.099. No change was made to the revenue estimate which at the last update was UK£500.0k. The Capital Markets industry in the United Kingdom is expected to see an average net income growth of 2.6% next year. The consensus price target increased from UK£1.38 to UK£2.34. Share price is up 49% to UK£1.58 over the past week.
공고 • Nov 06Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion.Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire VelosBio Inc. from A. M. Pappas Life Science Ventures V, LP, a fund of Pappas Capital, LLC, Arix Bioscience plc (LSE:ARIX) and other shareholders for $2.8 billion on November 5, 2020. The consideration will be paid in cash and is subject to certain customary adjustments. The sale of VelosBio is expected to deliver net proceeds of approximately $185 million to Arix Bioscience plc representing a 12x return on Arix's invested capital. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020. Gibson Dunn & Crutcher LLP acted as the legal advisor and J.P. Morgan Securities LLC acted as financial advisor to Merck & Co., Inc. Cooley LLP acted as the legal advisor and Centerview Partners LLC acted as the financial advisor to VelosBio Inc.
Valuation Update With 7 Day Price Move • Nov 06Market bids up stock over the past weekAfter last week's 50% share price gain to UK£1.60, the stock is trading at a trailing P/E ratio of 11.5x, up from the previous P/E ratio of 7.6x. This compares to an average P/E of 18x in the Capital Markets industry in the United Kingdom. Total return to shareholders over the past three years is a loss of 12%.
Is New 90 Day High Low • Nov 06New 90-day high: UK£1.60The company is up 109% from its price of UK£0.77 on 07 August 2020. The British market is down 2.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.19 per share.
Price Target Changed • Nov 06Price target raised to UK£1.71Up from UK£1.40, the current price target is an average from 3 analysts. The new target price is 6.9% above the current share price of UK£1.60. As of last close, the stock is up 32% over the past year.
Is New 90 Day High Low • Oct 01New 90-day high: UK£1.12The company is up 29% from its price of UK£0.86 on 03 July 2020. The British market is down 4.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Capital Markets industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£0.20 per share.
공고 • Aug 10Arix Bioscience plc to Report First Half, 2020 Results on Sep 08, 2020Arix Bioscience plc announced that they will report first half, 2020 results on Sep 08, 2020